- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01375179
Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis
This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory ulcerative colitis.
The study will provide safety and tolerability data in this subject population up to eight weeks of treatment with KRP203. Additionally, this study will evaluate the duration of a clinical response to KRP203 by following up responding subjects for an additional 12 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcerative colitis subjects. In total, approximately 72 subjects will be randomized into the study.
After 30 patients have completed the 8 week treatment period with KRP203 or placebo, there will be an interim analysis to determine preliminary efficacy. The study will consist of up to 28 day screening period (day -35 to -8), baseline period (day -7 to day -1), treatment period (day 1 to day 56), follow-up period and study completion.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Frankfurt am Main, Allemagne, 60318
- Novartis Investigative Site
-
Hamburg, Allemagne, 20148
- Novartis Investigative Site
-
Köln, Allemagne, 51103
- Novartis Investigative Site
-
-
-
-
-
Gent, Belgique, 9000
- Novartis Investigative Site
-
Leuven, Belgique, 3000
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hongrie, 1083
- Novartis Investigative Site
-
Debrecen, Hongrie, 4032
- Novartis Investigative Site
-
-
-
-
-
Nottingham, Royaume-Uni, NG7 2UH
- Novartis Investigative Site
-
-
Oxfordshire
-
Oxford, Oxfordshire, Royaume-Uni, OX3 9DU
- Novartis Investigative Site
-
-
-
-
-
Bern, Suisse, 3010
- Novartis Investigative Site
-
Zurich, Suisse, 8091
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Suède, 116 91
- Novartis Investigative Site
-
Stockholm, Suède, SE-141 86
- Novartis Investigative Site
-
Uppsala, Suède, 751 85
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Active disease defined by partial Mayo score and modified Baron score with disease extending at least 25 cm from the anal verge
- Subjects must have inadequately responded or intolerance to 5-ASA therapy
Exclusion Criteria:
- Subjects receiving treatment for UC (other than 5-ASAs and steroids) within the time frame mentioned in protocol
- Past or recent history of significant medical illness and/or clinically significant lab abnormalities including but not limited to hematology, clinical chemistry, urine analysis, ECG abnormalities, HIV, Hepatitis B/C
- Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, ophthalmic, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition, as assessed by the primary treating physician which, in the opinion of the investigator, would immunocompromise the subject and/or place the subject at unacceptable risk for participation in a study of an immunomodulatory therapy Other protocol-defined inclusion/exclusion criteria apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo
|
|
Expérimental: KRP203
Experimental Edit Experimental |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in clinical remission rate
Délai: 8 weeks
|
Difference between clinical remission rate of subjects on KRP203 versus placebo
|
8 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Délai: 8 weeks
|
Safety and tolerability of KRP203 assessed by the number of subjects with adverse events where KRP203 is given as an oral drug for 8 weeks once a day in ulcerative colitis subjects
|
8 weeks
|
Pharmacokinetic properties of KRP203 at steady-state using whole blood samples in patients with ulcerative colitis subjects
Délai: 8 weeks
|
8 weeks
|
|
Difference in pharmacokinetic levels
Délai: 12 weeks
|
To explore the relationship between KRP203 and KRP203-P pharmacokinetic levels and clinical efficacy outcomes such as the partial Mayo score and endoscopic modified Baron Score
|
12 weeks
|
Assessment of the pharmacodynamic effect of KRP203 on absolute lymphocyte count and leukocyte subsets in ulcerative colitis subjects
Délai: 12 weeks
|
12 weeks
|
|
Change in markers of inflammation
Délai: 12 weeks
|
Measure of the effect of KRP203 on markers of inflammation, including but not limited to ESR, CRP and fecal calprotectin/ lactoferrin as well as histopathological markers of gut mucosa using biopsy samples in ulcerative colitis subjects
|
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CKRP203A2201
- 2010-019970-33 (Numéro EudraCT)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur KRP203
-
Novartis PharmaceuticalsComplétéLupus érythémateux cutané subaiguGrèce, Allemagne, Italie